Your fact-checks will appear here
Clinical trial
High‑quality randomized trials have largely failed to show clinically meaningful benefits of ivermectin for COVID‑19: several large, double‑blind, placebo‑controlled trials found no reduction in hospi...
Controlled human trials and systematic reviews conducted to date do not demonstrate a clear, consistent dose–response increase in adverse events for ivermectin across the common therapeutic range and ...
A patchwork of randomized trials has evaluated ivermectin’s short‑term effects, but few registered RCTs explicitly set out to study long‑term safety; when long‑term endpoints are declared they most co...
Since 2022 several large, randomized, controlled trials and platform studies have reported on ivermectin for COVID‑19 and the aggregate finding from those high‑quality trials is a lack of clinically m...
The FDA has not authorized or approved ivermectin for the treatment or prevention of COVID‑19; its official position is that ivermectin should not be used for COVID‑19 outside of a clinical trial beca...
Large, high-quality randomized trials and recent meta-analyses converge on the conclusion that in outpatient settings, with no reliable evidence of reduced hospitalization or mortality and only incons...